FrankE.MottMD

Oncology • Houston, TX

Professor, Medicine, Medical College of GA at GRU

Join to view full profile

Are you Dr. Mott?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 64 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. Frank Mott, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center and is a Professor at Medical College of GA at GRU.

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1991 - 1994
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1988 - 1991
Texas A&M; Health Science Center College of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1980 - 2025
OK State Medical License 2020 - 2021
GA State Medical License 2013 - 2017
LA State Medical License 2010 - 2017
WI State Medical License 1989 - 2005

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Phase 2

Publications & Presentations

PubMed

358 citations
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone, William N. William, Annikka Weissferdt, Cheuk Hong Leung, Heather Lin
Nature Medicine. 2021-02-18
60 citations
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Renata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, M. Laura Rubin, Ying Yuan
Clinical Cancer Research. 2021-06-29
18 citations
Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer.
Sweet Ping Ng, Jason M. Johnson, G. Brandon Gunn, David I. Rosenthal, Heath D. Skinner
International Journal of Radiation Oncology, Biology, Physics. 2018-11-15

Press Mentions

Nasopharyngeal Carcinoma Survivor: My Journey to Becoming an OncologistAugust 17th, 2020
Optimal Sequencing and Patient Selection Investigated in NSCLCDecember 4th, 2017
OncLive® to Host State of the Science Summit™ on Advanced Non-Small Cell Lung CancerOctober 25th, 2017